Home > Search Results: Lebwohl, M.G.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.01 seconds.
Articles, 3 records found
Articles 3 records found  
1.
11 p, 1.5 MB Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up / Papp, Kim A (K Papp Clinical Research and Probity Medical Research) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Ohtsuki, M. (Jichi Medical University) ; Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden) ; Zeng, J. (AbbVie Inc.) ; Rubant, S. (AbbVie Inc.) ; Sinvhal, R. (AbbVie Inc.) ; Zhao, Y. (AbbVie Inc.) ; Soliman, A.M. (AbbVie Inc.) ; Alperovich, G. (AbbVie Inc.) ; Leonardi, C. (Central Dermatology. Richmond Heights)
Background: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long-term evaluation to assess the durability of their efficacy and safety profiles over time. [...]
2021 - 10.1111/bjd.20595
British journal of dermatology, Vol. 185 Núm. 6 (december 2021) , p. 1135-1145  
Detailed record - Creative Commons
2.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  
Detailed record - Creative Commons
3.
13 p, 3.0 MB Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks / Reich, Kristian (Dermatologikum Berlin) ; Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ; Iversen, Lars (Aarhus University Hospital (Aarhus, Dinamarca)) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Pau-Charles, I. (Almirall R&D) ; Igarashi, A. (NTT Medical Center Tokyo) ; Ohtsuki, M. (Jichi Medical University) ; Falqués, M. (Almirall R&D) ; Harmut, M. (Almirall R&D) ; Rozzo, S. (Sun Pharmaceuticals) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Cantrell, W. (University of Alabama at Birmingham) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Thaçi, Diamant (University of Lübeck) ; Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617  
Detailed record - Creative Commons

See also: similar author names
1 Lebwohl, M.
2 Lebwohl, M. G.
3 Lebwohl, Mark
1 Lebwohl, Mark G.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with